Design (Testphase)
Risk & Weakness
Downward Momentum
87
Findings
July 21, 2026
last calculated
Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Market filter active: the list shows 25 hits from US
Weak 3-month RS (≤ 10) and falling today — negative momentum.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
🔔 Watch scanner
Terms in This Scanner Explained
(17)
- ADR (Average Daily Range)
- The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
- AI Classification
- Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
- Analysis (Full Company Analysis)
- If the Analysis column shows "Read," there is an in-depth Minnow Street company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
- Avg/Yr 3Y (Average Annual Return)
- The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
- Earnings Date
- The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
- EPS (Earnings per Share)
- Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
- Free Cash Flow (FCF)
- Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
- Funda Rating (Fundamental Rating A+ to F)
- Our proprietary fundamental rating from -100 to +100 with a school-grade rank from A+ to F. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. A/A+ are the fundamentally strongest stocks in the universe.
- Market Capitalization (Mkt Cap)
- The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
- Momentum
- The driving force behind a price trend: stocks that have recently risen sharply statistically tend to keep rising more often than not. Momentum strategies therefore buy strength - not perceived bargains.
- Net Margin
- How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
- Operating Cash Flow (OCF)
- The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
- Piotroski F-Score
- A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
- Relative Strength (RS Rating)
- How much has a stock risen compared with every other stock? The RS Rating is a percentile from 1 to 99: RS 90 means the stock has outperformed 90% of all stocks (depending on the scanner, over 1 week, 1, 3, 6, or 12 months). Market leaders almost always carry high RS values - that is why relative strength is the core of many momentum strategies.
- Sector & Industry
- Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
- Stage (Weinstein Stages 1-4)
- Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
- Stress RS (Strength on Stress Days)
- A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.
Hit List
Filter ▾
Rating (traffic light)
Stage
Funda Rating
Piotroski
Columns ▾
This scanner's columns
Extra columns
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Stress RS | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HYMC Hycroft Mining Holding Corporation | 07/29 | +212 % | 51 5/23 | Stage 1 | D -22 | 4 of 9 | 2.0 | Gold | Neutral | — | — | Basic Materials | 18.80 $ | -2.7 % | -6.3 % | +573.9 % | −62.7 % | -40.6 % | 97 | 42 | 8.2 % | 8.0 % | 2.72 | — | 0.0 | — | 9.7 | — | — | -0.8 | — | -341.0 % | 0.0 % | -86.1 % | -26.8 % | 0.00 | — | -100.0 % | 0.0 % | 0.0 % | 0.6 | 33.1 % | 19.4 % | — |
| IBRX Immunitybio Inc | 08/04 | +57 % | 56 5/22 | Stage 2 | C +1 | 3 of 9 | 8.0 | Biotechnology | Uses AI | — | — | Healthcare | 7.50 $ | +269.7 % | +309.8 % | +182.6 % | −37.3 % | +66.9 % | 94 | 42 | 7.8 % | 7.0 % | 0.08 | — | 0.0 | 57.1 | — | — | — | -9.0 | -157.9 % | 99.3 % | 0.0 % | 0.0 % | -34.4 % | — | -134.5 % | +668.3 % | 0.0 % | 0.0 % | -23.1 | 17.6 % | 34.8 % | 1.0 (5) |
| ZURA Zura Bio Limited Class A Ordinary Shares | 08/13 | -21 % | 42 4/22 | Stage 1 | D -38 | 3 of 9 | 0.4 | Biotechnology | – | — | — | Healthcare | 5.30 $ | -17.8 % | +25.1 % | +280.4 % | −39.0 % | +245.1 % | 90 | 42 | 9.7 % | 8.0 % | -0.04 | — | 0.0 | — | — | — | — | -2.3 | — | — | 0.0 % | -41.0 % | -25.4 % | — | — | — | 0.0 % | 0.0 % | 23.1 | 78.6 % | 8.3 % | — |
| UAMY United States Antimony Corporation | 08/11 | +720 % | — | Stage 4 | D -24 | 1 of 9 | 0.0 | Other Industrial Metals & Mining | – | — | — | Basic Materials | 5.40 $ | +39.6 % | +9.6 % | +141.5 % | −65.2 % | +83.1 % | 78 | 50 | 8.1 % | 8.7 % | 0.35 | — | 78.1 | — | 7.7 | — | — | 14.7 | — | 22.1 % | -41.4 % | -19.7 % | -11.2 % | 0.00 | — | +162.8 % | 0.0 % | 0.0 % | 11.2 | 57.4 % | 22.0 % | — |
| RYAM Rayonier Advanced Materials | 08/04 | +32 % | 50 5/23 | Stage 1 | D -43 | 3 of 9 | 0.5 | Chemicals | – | — | — | Basic Materials | 8.20 $ | +37.0 % | +35.4 % | +109.2 % | −33.1 % | +82.8 % | 66 | 8 | 5.5 % | 4.7 % | 1.78 | — | 27.5 | 0.4 | 2.3 | — | 2.63 | 13.6 | — | 6.1 % | -32.8 % | -100.5 % | -0.1 % | 3.33 | — | -10.1 % | 0.0 % | 0.0 % | 3.7 | 80.6 % | 7.0 % | — |
| OLMA Olema Pharmaceuticals Inc | 08/10 | -15 % | 28 3/22 | Stage 1 | E -52 | 2 of 9 | 0.9 | Biotechnology | – | — | — | Healthcare | 11.40 $ | -57.9 % | -55.6 % | +165.9 % | −68.5 % | +256.1 % | 54 | 42 | 7.7 % | 7.0 % | 2.01 | — | 0.0 | — | 2.0 | — | — | -3.3 | — | — | 0.0 % | -42.9 % | -25.5 % | 0.00 | — | — | 0.0 % | 0.0 % | 12.7 | 119.4 % | 17.9 % | — |
| OIS Oil States International Inc | 07/30 | +5 % | 93 4/10 | Stage 1 | D -30 | 4 of 9 | 0.5 | Oil & Gas Equipment & Servic | – | — | — | Energy | 8.30 $ | +16.7 % | +16.1 % | +46.1 % | −45.2 % | +57.2 % | 40 | 12 | 3.5 % | 3.6 % | 1.09 | — | 19.2 | 0.7 | 0.9 | 7.1 | 1.01 | 10.8 | — | 21.9 % | -17.0 % | -17.8 % | 1.3 % | 0.13 | — | -3.4 % | 0.0 % | 0.0 % | 6.9 | 92.0 % | 4.1 % | — |
| JFB JFB Construction Holdings Class A Common Stock | 08/13 | — | 75 6/21 | Stage 4 | D -12 | 4 of 9 | 0.1 | Real Estate - Development | – | — | — | Real Estate | 3.70 $ | -33.0 % | -33.5 % | +73.0 % | −86.2 % | +85.6 % | 40 | 7 | 8.8 % | 8.9 % | — | — | 0.0 | 2.7 | 1.6 | — | — | 204.3 | — | 8.0 % | -22.9 % | -29.9 % | -16.7 % | 0.04 | — | +6.7 % | 0.0 % | 0.0 % | 9.3 | 4.7 % | 1,230.8 % | — |
| TARA Protara Therapeutics Inc | 08/10 | +20 % | 94 9/22 | Stage 4 | D -34 | 2 of 9 | 0.2 | Biotechnology | – | — | — | Healthcare | 4.10 $ | -25.0 % | -24.2 % | +39.9 % | −48.9 % | +564.3 % | 31 | 42 | 5.5 % | 6.2 % | 1.48 | — | 0.0 | — | 1.3 | — | — | 0.7 | — | — | 0.0 % | -37.3 % | -24.3 % | 0.02 | — | — | 0.0 % | 0.0 % | 17.8 | 82.4 % | 8.1 % | — |
| SPRU Spruce Power Holding Corp | 08/10 | -20 % | 83 8/25 | Stage 4 | D -39 | 4 of 9 | 0.0 | Solar | – | — | — | Technology | 2.30 $ | -46.6 % | -49.9 % | +33.2 % | −61.9 % | +133.5 % | 27 | 42 | 4.6 % | 6.3 % | 1.16 | — | 45.2 | 0.4 | 0.4 | 52.2 | — | 9.9 | — | 67.6 % | -12.2 % | -10.5 % | 1.7 % | 5.76 | — | +36.2 % | 0.0 % | 0.0 % | 1.4 | 35.7 % | 4.9 % | — |
| FBRX Forte Biosciences Inc | 08/13 | -23 % | 82 7/22 | Stage 1 | D -41 | 3 of 9 | 0.4 | Biotechnology | – | — | — | Healthcare | 47.50 $ | -33.4 % | -22.3 % | +45.3 % | −47.7 % | +240.7 % | 26 | 42 | 7.7 % | 8.6 % | 2.84 | — | 0.0 | — | 10.2 | — | — | 1.9 | — | — | 0.0 % | -188.4 % | -83.9 % | — | — | -100.0 % | 0.0 % | 0.0 % | -10.3 | 74.8 % | 7.2 % | — |
| KLRS Kalaris Therapeutics, Inc. | 08/12 | -31 % | 70 6/22 | Stage 1 | D -28 | 2 of 9 | 0.1 | Biotechnology | – | — | — | Healthcare | 4.00 $ | -47.0 % | -56.0 % | +86.4 % | −63.8 % | +335.2 % | 26 | 42 | 6.6 % | 7.3 % | — | — | 0.0 | — | — | — | — | 0.0 | — | — | 0.0 % | -66.6 % | -28.0 % | — | — | -85.5 % | 0.0 % | 0.0 % | 3.3 | 77.9 % | 9.2 % | — |
| WLK Westlake Chemical Corporation | 08/04 | -9 % | 50 5/23 | Stage 1 | E -57 | 2 of 9 | 9.8 | Specialty Chemicals | – | — | — | Basic Materials | 76.90 $ | +4.6 % | +2.5 % | +5.9 % | −38.4 % | +37.7 % | 23 | 11 | 3.5 % | 3.1 % | 0.62 | — | 18.1 | 0.9 | — | — | 1.70 | 35.1 | -5.8 % | 6.3 % | -14.9 % | -16.0 % | -1.0 % | — | 43.4 % | -8.0 % | 2.8 % | 69.4 % | 6.0 | 35.2 % | 12.1 % | 1.6 (14) |
| CATX Perspective Therapeutics Inc. | 08/12 | -19 % | 81 7/22 | Stage 1 | D -50 | 2 of 9 | 0.3 | Medical Devices | – | — | — | Healthcare | 2.90 $ | +9.1 % | +26.3 % | -27.0 % | −51.3 % | +331.1 % | 20 | 42 | 6.8 % | 6.5 % | 1.75 | — | 25.7 | 566.7 | 1.0 | — | — | -21.9 | — | -14,666.2 % | 0.0 % | -35.3 % | -20.3 % | 0.01 | — | -39.2 % | 0.0 % | 0.0 % | 8.2 | 76.7 % | 14.3 % | — |
| TRDA Entrada Therapeutics Inc | 08/05 | -17 % | — | Stage 1 | D -40 | 0 of 9 | 0.0 | Biotechnology | – | — | — | Healthcare | 6.30 $ | -29.6 % | -27.1 % | +7.1 % | −56.5 % | +162.2 % | 19 | 50 | 7.5 % | 7.2 % | -0.26 | — | 3,333.3 | — | 1.1 | — | — | 1.6 | — | -2,366.9 % | 0.0 % | -48.3 % | -26.8 % | 0.18 | — | -87.9 % | 0.0 % | 0.0 % | 6.1 | 78.7 % | 7.7 % | — |
| ODYS Odysight.ai Inc. Common Stock | 08/12 | -18 % | 97 12/25 | Stage 1 | D -32 | 2 of 9 | 0.1 | Scientific & Technical Instruments | – | — | — | Technology | 4.80 $ | +21.5 % | +27.9 % | -14.5 % | −64.3 % | +48.5 % | 19 | 42 | 6.2 % | 7.5 % | -0.48 | — | 0.0 | 71.0 | 3.2 | — | — | -2.0 | — | 34.3 % | 0.0 % | -63.1 % | -36.7 % | 0.03 | — | -23.9 % | 0.0 % | 0.0 % | 1.1 | 25.8 % | 0.5 % | — |
| OSIS OSI Systems Inc | 08/20 | +28 % | 79 8/25 | Stage 4 | C +2 | 3 of 9 | 3.7 | Electronic Components | – | — | — | Technology | 210.50 $ | -15.4 % | -20.9 % | -0.9 % | −29.8 % | +37.2 % | 18 | 30 | 4.0 % | 4.1 % | 1.20 | 25.0 | 19.3 | 2.0 | 4.0 | 58.4 | 1.61 | 16.7 | 13.1 % | 32.8 % | 8.4 % | 17.2 % | 6.1 % | 1.12 | 35.0 % | +11.3 % | 0.0 % | 0.0 % | 8.6 | 124.6 % | 17.8 % | 1.1 (7) |
| PATK Patrick Industries Inc | 07/30 | +29 % | 21 4/31 | Stage 4 | C 0 | 4 of 9 | 3.0 | Recreational Vehicles | – | — | — | Consumer Cyclical | 87.40 $ | -18.9 % | -16.5 % | +0.7 % | −37.6 % | +28.4 % | 17 | 31 | 4.0 % | 3.7 % | 1.09 | 24.5 | 18.1 | 0.8 | 2.6 | 15.6 | 3.46 | 10.4 | 6.5 % | 23.1 % | 3.5 % | 11.7 % | 5.4 % | 1.35 | 36.9 % | +6.3 % | 2.2 % | 40.7 % | 6.7 | 112.4 % | 9.1 % | 1.3 (9) |
| SITE SiteOne Landscape Supply Inc | 07/29 | -11 % | 9 2/29 | Stage 4 | C +6 | 3 of 9 | 5.2 | Industrial Distribution | – | — | — | Industrials | 102.80 $ | -15.4 % | -9.9 % | -7.8 % | −31.8 % | +39.8 % | 16 | 73 | 4.4 % | 3.8 % | 1.34 | 33.9 | 24.7 | 1.1 | 3.1 | 21.1 | 2.52 | 15.8 | -2.8 % | 34.9 % | 3.2 % | 10.0 % | 4.5 % | 0.70 | 46.9 % | +3.6 % | 0.0 % | 0.0 % | 7.8 | 115.8 % | 7.0 % | 1.6 (11) |
| CLB Core Laboratories NV | 07/22 | -16 % | 29 1/10 | Stage 4 | C -5 | 4 of 9 | 0.5 | Oil & Gas Equipment & Servic | – | — | — | Energy | 11.20 $ | -27.3 % | -33.9 % | -7.6 % | −46.4 % | +45.0 % | 15 | 20 | 4.7 % | 4.6 % | 1.01 | 18.1 | 17.2 | 1.0 | 1.9 | 26.7 | 1.44 | 9.8 | — | 19.9 % | 5.5 % | 11.1 % | 4.9 % | 0.62 | — | +0.5 % | 0.4 % | 5.9 % | 6.9 | 113.7 % | 28.6 % | — |
| OFIX Orthofix Medical Inc | 08/04 | -17 % | 40 4/22 | Stage 4 | C +5 | 4 of 9 | 0.4 | Medical Devices | – | — | — | Healthcare | 11.60 $ | -40.0 % | -36.1 % | -13.3 % | −45.2 % | +61.1 % | 11 | 42 | 4.9 % | 5.6 % | 0.71 | — | 500.0 | 0.4 | — | — | 48.83 | 25.6 | — | 71.0 % | -7.3 % | -13.4 % | -3.3 % | — | — | +2.9 % | 0.0 % | 0.0 % | 4.7 | 92.1 % | 5.6 % | — |
| DTI Drilling Tools International Corp. | 08/12 | -16 % | 57 2/10 | Stage 1 | D -33 | 3 of 9 | 0.1 | Oil & Gas Equipment & Services | – | — | — | Energy | 2.30 $ | -9.8 % | -31.1 % | -34.7 % | −58.7 % | +132.0 % | 11 | 6 | 6.3 % | 5.1 % | -0.60 | — | 22.6 | 0.5 | 0.6 | — | 2.51 | 5.0 | — | 73.4 % | -2.4 % | -3.0 % | 1.0 % | 0.64 | — | +3.4 % | 0.0 % | 0.0 % | 5.5 | 19.8 % | 1.9 % | — |
| SAMG Silvercrest Asset Management Group Inc | 07/30 | -14 % | 30 3/22 | Stage 4 | D -18 | 3 of 9 | 0.1 | Asset Management | – | — | — | Financial Services | 9.80 $ | -30.4 % | -29.6 % | -28.7 % | −39.3 % | +93.8 % | 11 | 4 | 6.2 % | 4.1 % | 0.68 | 35.2 | 11.8 | 0.6 | 1.9 | 9.2 | 0.98 | 10.0 | — | 31.2 % | 2.1 % | 4.7 % | 2.5 % | 0.61 | — | +1.4 % | 8.0 % | 113.5 % | 6.1 | 68.6 % | 2.4 % | — |
| SBC SBC Medical Group Holdings Incorporated | 08/12 | -23 % | 60 7/29 | Stage 4 | C +4 | 3 of 9 | 0.3 | Consulting Services | – | — | — | Industrials | 3.00 $ | -28.8 % | -29.5 % | -29.3 % | −44.7 % | +167.3 % | 11 | 16 | 5.0 % | 4.8 % | 0.59 | 8.3 | 6.8 | 2.0 | 1.3 | 7.5 | — | 2.9 | — | 70.8 % | 24.1 % | 16.5 % | 11.3 % | 0.20 | — | -15.5 % | 0.0 % | 0.0 % | 11.8 | 1.4 % | 2.0 % | — |
| ONT Onterris | 08/05 | -19 % | — | Stage 4 | C 0 | 3 of 9 | 0.0 | Waste Management | – | — | — | Industrials | 19.80 $ | -32.3 % | -22.3 % | -16.0 % | −43.2 % | +50.3 % | 10 | 50 | 6.5 % | 6.3 % | 1.66 | 125.4 | 0.0 | — | 1.5 | — | — | 13.0 | — | 40.4 % | 0.7 % | 1.2 % | 1.1 % | 0.88 | — | +19.3 % | 0.0 % | 0.0 % | 4.1 | 99.5 % | 9.4 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Weak 3-month RS (≤ 10) and falling today — negative momentum.
All scanners are recalculated daily across the entire stock universe — most recently on 21. July 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 87 stocks pass this scanner's criteria (as of 21. July 2026). The 25 strongest hits are shown.
Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Funda Rating ≥ +10) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Altman Z: Distress Zone
- Below the 50- & 200-SMA
- Beneish M-Score
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- Kathy Donnelly: Liquid Movers Down
- Mike Webster: Overextended (Webby RSI)
- Near 52-Week Low
- Pradeep Bonde: $ Breakout Bearish
- Pradeep Bonde: 4% Breakout Bearish
- Qullamaggie: Parabolic (Short-Watch)
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Insolvency Candidate
- Weakness Cluster
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.